At least $29 per share in adjusted earnings is what Elevance Health now forecasts for 2026.

Elevance Health (ELV) reported Q3 2026 revenue of $50.4B, up 0.7% YoY, with net income rising to $1.37B. EPS increased to $6.99. The company raised its full-year 2026 guidance for earnings and cash flow. Medicare membership declined, but Carelon segment revenue grew 5%. ELV stock closed at $440.18, up 2.31%.

Elevance Health (ELV) reported Q3 net income of $1.365B, up 14.8% YoY, with EPS rising 17.9% to $6.27. Revenue increased 0.7% to $50.44B. The company raised FY26 EPS guidance to at least $22.00 and adjusted EPS to at least $29.00, and declared a $1.72 per share dividend. Shares gained 2.23% in pre-market trading.

Elevance Health reported Q3 net income of $1.36B, up 15% YoY. Costs eased in Medicare and ACA plans, improving the benefit expense ratio. The company raised its full-year EPS outlook to $22.00 from $20.10, citing continued momentum. Elevance is the second-largest U.S. health insurer, operating Anthem Blue Cross Blue Shield plans and Medicaid services.

Nasdaq futures rose as SpaceX and Super Micro Computer reported strong earnings, boosting AI-related stocks. SpaceX gained 7.2% after reporting its first profit and discussing a potential merger with Tesla. Super Micro jumped 10.9% on strong revenue forecasts. Netflix fell 6.6% after a weak profit forecast. Other tech and space stocks also saw gains. Oil prices remained high, and Fed rate hike expectations persist.

Elevance Health (ELV) reported Q3 2026 revenue of $50.44B, flat YoY but beating estimates by 3.1%. Its customer base reached 44.88M, with average annual spending increasing. Adjusted operating margin was 2.7%, down 1.3 points YoY. EPS grew 14.1% YoY to $6.99, exceeding expectations. Analysts project flat revenue and a 6.6% EPS decline over the next 12 months.

Elevance Health stock rose 1.8% in pre-market trading after reporting Q3 2026 earnings of $6.99 per share, exceeding estimates of $4.70, with revenue at $50.4 billion. The company raised full-year EPS guidance to at least $29.00 and increased operating cash flow guidance to at least $6.5 billion. CEO Gail K. Boudreaux cited strong execution across the portfolio. Guggenheim raised its price target to $460, and the company declared a Q4 dividend of $1.72 per share.